MK-1708 + itraconazole

MK-1708 + itraconazole is a drug combination utilized in clinical pharmacology studies to evaluate the pharmacokinetic profile of MK-1708, an investigational small molecule developed by Merck Sharp & Dohme (MSD). MK-1708 is currently in Phase 1 development for the treatment of neurodegenerative conditions, specifically Alzheimer's Disease and Amyotrophic Lateral Sclerosis (ALS). In this combination, itraconazole serves as a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme. The primary objective of co-administering these agents is to conduct a drug-drug interaction (DDI) study (such as NCT06586606) to determine if MK-1708 is a substrate of CYP3A4 and to quantify the impact of enzyme inhibition on its systemic exposure and clearance.